Elixir, maker of botanical alternatives, is building a disruptive herbal alternative platform designed to safely replicate the behavioral ritual of vaping—without nicotine, THC, or regulatory flavor exposure. Utilizing FDA GRAS-certified botanicals, proprietary oil-free formulations, and an aromatherapy classification strategy, the company positions itself adjacent to the $200B global vaping category rather than directly within it.
Elixir operates two flagship product lines: Botanika, a nicotine-alternative personal diffuser, and Epothecary, a functional supplement line designed for fast-acting delivery. The company has surpassed 150,000 units sold, achieved a 33% reorder rate within 30 days, and secured placement in more than 300 retail locations nationwide. Expansion into convenience, specialty wellness chains, and select big-box distribution is underway.
Happy Wellness Group has supported Elixir as a strategic advisory and ecosystem partner, helping the company engage relationships across its curated, wellness-focused founder and investor community.
In the company’s most recent financing activity, investor participation included capital commitments from relationships connected through the HWG ecosystem, with investments completed directly between investors and the issuer.
HWG remains committed to providing advisory and platform support as Elixir scales retail distribution and national brand awareness.
Disclaimer:
HWG is not a broker-dealer and does not solicit or execute securities transactions. Any investments referenced were made independently by investors directly with the issuer or through registered intermediaries.
